Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine(R), the reference product, in patients with advanced cancer potentially sensitive to vinorelbine. Equivalence was demonstrated by a statistical comparison of both the areas under the curve (AUC) and maximum plasma concentrations (Cmax). The Company anticipates safety and full clinical results will be available during the first quarter of 2008. Results from this study will be submitted for presentation at an appropriate medical conference.

"We're very pleased with these results, which we believe will provide sufficient clinical data to support a Section 505(b)(2) New Drug Application," said Evan M. Levine, chief executive officer of ADVENTRX. "We have a meeting scheduled with the FDA in December to discuss our commercial manufacturing plans. After we receive the FDA's written comments, we intend to provide an update regarding our NDA timeline for ANX-530."

ANX-530 is a novel emulsion formulation of vinorelbine. Vinorelbine, marketed under the brand name Navelbine(R), also available as generic vinorelbine, is an anti-cancer agent approved to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million.

The bioequivalence study of ANX-530 was a crossover comparison of ANX-530 and Navelbine with a primary objective of demonstrating the pharmacokinetic equivalence of ANX-530
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  Upsher-Smith Laboratories, Inc., a specialty ... treatments for diseases of the central nervous system, ... website, upsher-smith.com . The new site celebrates ... of the company,s mission statement – Advancing Pharmacotherapy, ... around people with a story to tell, a ...
(Date:5/20/2013)... , May 20, 2013 /PRNewswire-iReach/ -- Specific Technologies, ... first study demonstrating detection of pathogenic bacteria, including ... and Bacillus anthracis which feature ... list of potential bio-threats. This seminal study, conducted ... Laboratory, Salisbury (DSTL), ...
(Date:5/20/2013)... -- TRACE International today released its Global Enforcement Report ... individuals and government or business entities for bribery and ... 2012 is the third in an annual series from ... "Although the number of outbound enforcement actions fell last ... said Alexandra Wrage , TRACE Founder ...
Breaking Medicine Technology:Upsher-Smith Introduces Newly Redesigned Corporate Website 2Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3
... Feb. 23, 2012 Escalon Medical Corp.,s (Nasdaq Market: ... it has successfully completed the outsourced manufacturing of its ... instruments for sale. Drew has also identified an outsourcing ... units being available for sale by the summer of ...
... 23, 2012 The management of ReBuilder Medical Technologies, ... has filed complaints with the U.S. Securities Exchange Commission ... certain traders of the Company shares may have engaged ... the Company,s shares.   The firmed has hired a forensic ...
Cached Medicine Technology:Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 2Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 3Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 4ReBuilder (RBRM) Files Complaints Against Stock Traders 2
(Date:5/21/2013)... Southborough, MA (PRWEB) May 21, 2013 ... a global leader in the development and standardization ... method, jointly developed by Brunswick Laboratories and the ... measuring antioxidants in foods. This decision comes after ... (ERP) chaired by James Harnly of the U.S. ...
(Date:5/21/2013)... Kansas City, MO (PRWEB) May 21, 2013 ... announcing updated news for women who have used the ... patients filing lawsuits alleging blood clot injuries has increased ... those using popular prescription drugs and devices with the ... can find out if others are experiencing similar side ...
(Date:5/21/2013)... Fulton, MD (PRWEB) May 21, 2013 ... don’t often think about. Not only is it more difficult ... down can become tricky. Fortunately, there are a variety of ... extra help. One such product is the raised toilet seat. ... the floor, making it easier to stand back up or ...
(Date:5/20/2013)... CA (PRWEB) May 21, 2013 USA ... A Transcendent Approach to Peak Performance" won the top ... Non-Fiction Category. Chosen over a multitude of international ... global attention and critical acclaim from both mainstream and ... levels - mentally, physically and spiritually. , ...
(Date:5/20/2013)... 2013 Heritage Woods of Gurnee ... County, Illinois, is hosting Breakfast and Bingo at 8:30 ... is located at 3775 Grand Ave. in Gurnee, Illinois, ... Medicaid, who need some help to maintain their independence. ... games of bingo," says Tammy Temaner-Rosas, Director of Marketing ...
Breaking Medicine News(10 mins):Health News:AOAC International Approves ORAC as First Action Official Method 2Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:JustHomeMedical.com Launches Raised Toilet Seats Category 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2
... The US-China Business,Council (USCBC) today encouraged American ... in China in response to the devastating earthquake,that ... member companies have already pledged several million dollars ... to earthquake victims and many,have established matching funds ...
... release earlier this,year, the FDA issued a Public Health ... and cold products should not,be used to treat infants ... and potentially life-threatening side effects can occur from such,use., ... that OTC cough,and cold medicines not be used for ...
... cholesterol-lowering drugs showed some benefits in preliminary trial ... appear to be associated with a lower risk ... fibrillation in postmenopausal women with coronary disease. , ... atrial fibrillation, but it certainly supports the hypothesis ...
... SAN DIEGO, May 15 - RealAge, Inc., ... Life to the Youngest" and,pursue health and wellness ... Award at the 2008 Pharmaceutical Advertising and Marketing,Excellence ... The,RealAge/ARD Marketing Valtrex(R) campaign was honored in the ...
... HIV/AIDS Fundraising Spectacular Takes Place June 14 & 15 at Paris Las ... ... May 15 It,s an all-original, all-singing,all-dancing musical journey across America when ... production show. The spectacular is staged June 14 and 15 in Le,Theatre ...
... May 15 /PRNewswire-FirstCall/ - SXC Health Solutions, Corp.,("SXC" or ... leading provider of,pharmacy benefits management services, announces that Mark ... CFO, will present at the,FBR Capital Markets 12th Annual ... SXC,s presentation will take place on Thursday, May 29,2008 ...
Cached Medicine News:Health News:US Companies Aid Chinese Earthquake Victims 2Health News:US Companies Aid Chinese Earthquake Victims 3Health News:US Companies Aid Chinese Earthquake Victims 4Health News:US Companies Aid Chinese Earthquake Victims 5Health News:US Companies Aid Chinese Earthquake Victims 6Health News:US Companies Aid Chinese Earthquake Victims 7Health News:Saline is Safe Alternative to Harmful Cough and Cold Products 2Health News:Statins May Help Older Women Control Irregular Heartbeat 2Health News:RealAge Wins Silver PhAME Award 2Health News:Golden Rainbow Takes a Musical Journey for Its 22nd Annual 'Ribbon of Life' Production Show 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: